Notably, in a study on the combination of chemotherapy and targeted therapy in diffuse large B-cell lymphoma (DLBCL), an increase in CD68+TAMs post-chemotherapy alone indicated a poor prognosis, while an increase in CD68+TAMs content post-rituximab treatment had a positive effect on the prognosis of patients [29]. The gene discussed is CD68; the disease is diffuse large B-cell lymphoma.